Structure Therapeutics’ (GPCR) Overweight Rating Reiterated at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued to investors on Friday, Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 65.44% from the stock’s current price.

Separately, Lifesci Capital restated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $85.71.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $39.29 on Friday. The business has a fifty day simple moving average of $39.34 and a 200 day simple moving average of $46.82. Structure Therapeutics has a one year low of $21.79 and a one year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. Analysts predict that Structure Therapeutics will post -0.98 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP raised its stake in shares of Structure Therapeutics by 404.0% during the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after buying an additional 3,504,747 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after purchasing an additional 1,333,333 shares during the last quarter. Federated Hermes Inc. increased its holdings in Structure Therapeutics by 104.2% in the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock valued at $92,411,000 after purchasing an additional 1,157,006 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock valued at $90,752,000 after acquiring an additional 1,607,525 shares during the period. Finally, FMR LLC grew its holdings in shares of Structure Therapeutics by 28.5% in the 3rd quarter. FMR LLC now owns 1,590,335 shares of the company’s stock valued at $80,185,000 after buying an additional 352,600 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.